NCT07528547 Hypersight and Ethos In Pediatric Radiotherapy
| NCT ID | NCT07528547 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Health Network, Toronto |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-04-14 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2026-04-14 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a single-center, prospective pilot study evaluating the utility of HyperSight CBCT imaging and Ethos adaptive radiation planning in pediatric patients receiving radiation therapy for non-cranial tumors. Twenty patients aged 18 or under will be enrolled. Participants will receive standard-of-care radiation therapy, with the addition of twice-weekly HyperSight CBCT scans. These scans will be used to assess anatomical changes and generate adapted radiation plans using the Ethos platform. Radiation oncologists and radiation therapists will independently evaluate the need for adaptation, and adapted vs. scheduled plans will be compared using dosimetric and anatomical similarity metrics. An optional sub-study will allow anonymized imaging and planning data to be shared with Varian Medical Systems. The study duration will match the patient's treatment course, typically 1-6 weeks, with no additional follow-up beyond standard care.
Eligibility Criteria
Inclusion Criteria: * Patient (paediatric or adolescent) age 18 or under receiving at least 5 days of radiation therapy * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3 Exclusion Criteria: \- Patients with primary cranial tumours will be excluded due to the low expected utility of non-contrast CT scans in the delineation of brain edema and brain substructures.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07528547 clinical trial?
This trial is open to participants of all sexes, up to 18 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07528547 currently recruiting?
Yes, NCT07528547 is actively recruiting participants. Contact the research team at dana.keilty@uhn.ca for enrollment information.
Where is the NCT07528547 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT07528547 clinical trial?
NCT07528547 is sponsored by University Health Network, Toronto. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.